NDAORALCAPSULEPriority Review
Approved
Nov 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYPRINE (trientine hydrochloride) is an oral small-molecule chelating agent approved in 1985 for Wilson's disease, a rare genetic disorder of copper metabolism. It binds excess copper and promotes urinary excretion, preventing neurological and hepatic damage.
$0.702MPart D
LOE ApproachingNiche rare-disease product with minimal Part D spending; small team focus on specialty pharmacy and patient support programs rather than large-scale commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYPRINE offers a niche career path suited to professionals passionate about rare disease management rather than high-volume commercial environments. Working on this product emphasizes deep clinical expertise, patient relationship building, and operational efficiency in a small, specialized market.
Product ManagerMedical Science Liaison
Worked on SYPRINE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.